Literature DB >> 25006448

Role of vascular endothelial growth factor signaling in Schistosoma-induced experimental pulmonary hypertension.

Jacob J Chabon1, Liya Gebreab1, Rahul Kumar1, Elias Debella1, Takeshi Tanaka1, Dan Koyanagi1, Alexandra Rodriguez Garcia1, Linda Sanders1, Mario Perez1, Rubin M Tuder2, Brian B Graham2.   

Abstract

There is significant evidence that Th2 (T helper 2)-mediated inflammation supports the pathogenesis of both human and experimental animal models of pulmonary hypertension (PH). A key immune regulator is vascular endothelial growth factor (VEGF), which is produced by Th2 inflammation and can itself contribute to Th2 pulmonary responses. In this study, we interrogated the role of VEGF signaling in a murine model of schistosomiasis-induced PH with a phenotype of significant intrapulmonary Th2 inflammation, vascular remodeling, and elevated right ventricular pressures. We found that VEGF receptor blockade partially suppressed the levels of the Th2 inflammatory cytokines interleukin (IL)-4 and IL-13 in both the lung and the liver after Schistosoma mansoni exposure and suppressed pulmonary vascular remodeling. These findings suggest that VEGF positively contributes to schistosomiasis-induced vascular inflammation and remodeling, and they also provide evidence for a VEGF-dependent signaling pathway necessary for pulmonary vascular remodeling and inflammation in this model.

Entities:  

Keywords:  VEGF; inflammation; pulmonary hypertension; schistosomiasis

Year:  2014        PMID: 25006448      PMCID: PMC4070790          DOI: 10.1086/675992

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   3.017


  34 in total

1.  Prevalence of pulmonary hypertension in patients with hepatosplenic Mansonic schistosomiasis--prospective study.

Authors:  Roberto de Cleva; Paulo Herman; Vincenzo Pugliese; Bruno Zilberstein; William Abrão Saad; Joaquim Jose Gama Rodrigues; Antonio Atílio Laudanna
Journal:  Hepatogastroenterology       Date:  2003 Nov-Dec

Review 2.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

3.  IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury.

Authors:  J Corne; G Chupp; C G Lee; R J Homer; Z Zhu; Q Chen; B Ma; Y Du; F Roux; J McArdle; A B Waxman; J A Elias
Journal:  J Clin Invest       Date:  2000-09       Impact factor: 14.808

Review 4.  Pulmonary hypertension and inflammation.

Authors:  R M Tuder; N F Voelkel
Journal:  J Lab Clin Med       Date:  1998-07

5.  Dysregulation of the IL-13 receptor system: a novel pathomechanism in pulmonary arterial hypertension.

Authors:  Matthias Hecker; Zbigniew Zaslona; Grazyna Kwapiszewska; Gero Niess; Anna Zakrzewicz; Eduard Hergenreider; Jochen Wilhelm; Leigh M Marsh; Daniel Sedding; Walter Klepetko; Jürgen Lohmeyer; Stefanie Dimmeler; Werner Seeger; Norbert Weissmann; Ralph T Schermuly; Nikolaus Kneidinger; Oliver Eickelberg; Rory E Morty
Journal:  Am J Respir Crit Care Med       Date:  2010-06-03       Impact factor: 21.405

6.  Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni.

Authors:  Brian B Graham; Jacob Chabon; Liya Gebreab; Jennifer Poole; Elias Debella; Laura Davis; Takeshi Tanaka; Linda Sanders; Nina Dropcho; Angela Bandeira; R William Vandivier; Hunter C Champion; Ghazwan Butrous; Xiao-Jing Wang; Thomas A Wynn; Rubin M Tuder
Journal:  Circulation       Date:  2013-08-19       Impact factor: 29.690

7.  Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling.

Authors:  Joseph T Crossno; Chrystelle V Garat; Jane E B Reusch; Kenneth G Morris; Edward C Dempsey; Ivan F McMurtry; Kurt R Stenmark; Dwight J Klemm
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2006-12-22       Impact factor: 5.464

8.  Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats.

Authors:  Masahiko Oka; Noriyuki Homma; Laimute Taraseviciene-Stewart; Kenneth G Morris; Donatas Kraskauskas; Nana Burns; Norbert F Voelkel; Ivan F McMurtry
Journal:  Circ Res       Date:  2007-03-01       Impact factor: 17.367

9.  Inhibition of 5-lipoxygenase-activating protein (FLAP) reduces pulmonary vascular reactivity and pulmonary hypertension in hypoxic rats.

Authors:  N F Voelkel; R M Tuder; K Wade; M Höper; R A Lepley; J L Goulet; B H Koller; F Fitzpatrick
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

10.  Temporal hemodynamic and histological progression in Sugen5416/hypoxia/normoxia-exposed pulmonary arterial hypertensive rats.

Authors:  Michie Toba; Abdallah Alzoubi; Kealan D O'Neill; Salina Gairhe; Yuri Matsumoto; Kaori Oshima; Kohtaro Abe; Masahiko Oka; Ivan F McMurtry
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-15       Impact factor: 4.733

View more
  2 in total

Review 1.  Schistosome Egg Migration: Mechanisms, Pathogenesis and Host Immune Responses.

Authors:  Alice H Costain; Andrew S MacDonald; Hermelijn H Smits
Journal:  Front Immunol       Date:  2018-12-20       Impact factor: 7.561

2.  Experimental animal models of pulmonary hypertension: Development and challenges.

Authors:  Xiao-Han Wu; Jie-Ling Ma; Dong Ding; Yue-Jiao Ma; Yun-Peng Wei; Zhi-Cheng Jing
Journal:  Animal Model Exp Med       Date:  2022-03-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.